Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $25.0952W HIGH $94.90
Volume
593.23 K
Value Traded
19.05 M
Short % Float
9.51%
-7.43%Week
-35.42%1 Month
-50.54%3 Month
-52.92%6 Month
+56.76%5 Year
+56.76%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.78 B
EPS (TTM)
-3.01
P/E Ratio
-
Ent. Value
435.46 M
Total Shares
69.62 M
Float Shares
69.46 M
Insiders
2.60%
Institutions
89.45%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
GPCR Catalyst Timeline
Dated clinical, regulatory and corporate events for Structure Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Structure Therapeutics Inc.
133Total events
11Upcoming
31Tier-1 (high impact)
2023 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutACCG-2671Clinical Data
Positive topline data for ACCG-2671 in Phase 1/2a SAD trial
healthy participants without obesitysource ↗
▲First Patient DosedACCG-2671Trial
First participants dosed with ACCG-2671 in 12-week MAD portion of Phase 1/2a trial
obesitysource ↗
▲Full ResultsAleniglipronClinical Data
Positive 72-week results for aleniglipron in ACCESS OLE
obesitysource ↗
▲Long Term DataAleniglipronClinical Data
Positive 72-week results for aleniglipron in ACCESS OLE trial
obesitysource ↗
●Enrollment UpdateAleniglipronTrial
Enrollment ongoing in ACCOMPLISH-1 and ACCOMPLISH-2 Phase 3 trials
obesity or overweight with at least one weight-related comorbidity; obesity or overweight and T2DMsource ↗
▲Topline ReadoutAleniglipronClinical Data
Positive 72-week results for aleniglipron in ACCESS OLE trial
obesitysource ↗
▲First Patient DosedACCG-2671Trial
First participants dosed in 12-week MAD portion of ACCG-2671 Phase 1/2a trial
obesitysource ↗
▲First Patient DosedAleniglipronTrial
First patients dosed in Phase 3 ACCOMPLISH program
chronic weight managementsource ↗
●Trial InitiationAleniglipronTrial
Phase 3 ACCOMPLISH program initiated in August 2026
obesity or overweight with at least one weight-related comorbidity; obesity or overweight and T2DMsource ↗
◆Topline ReadoutAleniglipronClinical Data
Topline results from ACCESS OLE
obesity and overweightsource ↗
◆Topline ReadoutACCG-2671Clinical Data
Phase 1 clinical data for ACCG-2671 anticipated
obesitysource ↗
◆Poster PresentationAleniglipronPresentation
Poster presentation of ACCESS II trial of aleniglipron at ADA 86th Scientific Sessions
obesitysource ↗
◆Poster PresentationAleniglipronPresentation
Late-breaking poster on lower starting dose of aleniglipron to improve GI tolerability at ADA 86th Scientific Sessions
obesitysource ↗
◆Poster PresentationACCG-2671Presentation
Late-breaking poster on combination of aleniglipron and ACCG-2671 in obese NHPs at ADA 86th Scientific Sessions
obesitysource ↗
◆Poster PresentationPresentation
Late-breaking poster on conditioned taste avoidance profiles of GLP-1 and amylin peptides and small molecule amylin agonists at ADA 86th Scientific Sessions
obesitysource ↗
◆Poster PresentationACCG-2671Presentation
Late-breaking poster on combination of aleniglipron and ACCG-2671 in obese NHPs at ADA 86th Scientific Sessions
obesitysource ↗
◆Oral PresentationAleniglipronPresentation
Oral presentation of ACCESS Phase 2b trial of aleniglipron at ADA 86th Scientific Sessions
obesity and overweightsource ↗
▲PublicationAleniglipronPresentation
Nature Medicine publication of Phase 2b ACCESS trial results
obesitysource ↗
◆Trial InitiationAleniglipronTrial
Anticipated initiation of Phase 3 program
obesity and/or overweight with at least one weight-related comorbiditysource ↗
◆End Of Phase 2 MeetingAleniglipronFDA Meeting
End-of-Phase 2 meeting with FDA scheduled
obesity and/or overweightsource ↗
▲Topline ReadoutAleniglipronClinical Data
Positive topline data from Phase 2 ACCESS II trial
obesity and/or overweight with at least one weight-related comorbiditysource ↗
▲Interim AnalysisAleniglipronTrial
Interim data from body composition study
obesity and/or overweightsource ↗
◆Oral PresentationAleniglipronPresentation
Conference call and webcast to discuss data
obesity and/or overweightsource ↗
▲Topline ReadoutAleniglipronClinical Data
Positive topline data from Phase 2 ACCESS II study
obesity and overweightsource ↗
▲FDA Feedback ReceivedAleniglipronFDA Meeting
Positive end-of-Phase 2 feedback from FDA
obesity and overweightsource ↗
●Timing GuidanceAleniglipronPresentation
Previously reported interim ACCESS OLE results at 56 weeks in March 2026
obesitysource ↗
◆Topline ReadoutAleniglipronClinical Data
Topline 44-week data from ACCESS II study with higher doses expected
obesity and overweightsource ↗
◆End Of Phase 2 MeetingAleniglipronFDA Meeting
Planned Type B End-of-Phase 2 meeting with FDA
obesity and/or overweight with at least one weight-related comorbiditysource ↗
◆Topline ReadoutAleniglipronClinical Data
Topline 36-week data from ACCESS II study
obesity and overweightsource ↗
◆Trial InitiationACCG-2671Trial
Phase 1 study initiation of ACCG-2671
obesity or overweight with comorbiditiessource ↗
▼Equity OfferingCorporate
Closing of upsized $747.5M public offering of ADSs and pre-funded warrants
▼Equity OfferingCorporate
Pricing of upsized $650 million public offering of ADSs and pre-funded warrants
▼Equity OfferingCorporate
Proposed $500 million public offering of ADSs and pre-funded warrants
▲Topline ReadoutAleniglipronClinical Data
Positive topline data from Phase 2b ACCESS study
obesity and/or overweight with at least one weight-related comorbiditysource ↗
◆Oral PresentationAleniglipronPresentation
Conference call and webcast to discuss ACCESS topline data
obesitysource ↗
Past FDA Catalysts and PDUFA Decisions
How GPCR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | ACCG-2671 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C51 / 100
Pipeline Score
$679M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.4x
rNPV / MCap
Top 16%
Micro Cap(rank 106 of 660)
Percentile Rank
Structure Therapeutics Inc. carries a moderate pipeline score (51/100), with $1.7B risk-adjusted pipeline value, led by Aleniglipron in Obesity (Phase 3), across $91B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aleniglipron Small moleculeNCT06703021 | Obesity | Phase 3 | COMPLETED | 4,785 | Jan 12, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every GPCR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Coll Crespo BlasOfficer (CHIEF MEDICAL OFFICER) | Sell | -4,008 1,157 held | $36.15 | 09/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GPCR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 3.2 % (3.2 %) | 351.84 M | 6.56 M |
GPCR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GPCR ranks across every disease it competes in
Competitive Position is a premium feature
See how GPCR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGPCR News
GPCR▼ -14.7%on this news
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
Structure Therapeutics has reported positive clinical data from its oral small molecule programs for chronic weight management. ACCG-2671 showed a 3.3% body weight reduction in a Phase 1/2a trial, while aleniglipron achieved up to 16.2% weight loss over 72 weeks. Both drugs exhibited favorable safety profiles, with no serious adverse events. The company is advancing its clinical trials, with topline data expected in the coming years.
Read more →GPCRStructure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Structure Therapeutics Inc. announced its participation in three healthcare investor conferences in September 2026. The events will include fireside chats and one-on-one meetings, providing opportunities for investors to engage with the company's management. Structure Therapeutics is focused on developing novel oral small molecule therapeutics for metabolic diseases, particularly obesity.
Read more →GPCRStructure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Structure Therapeutics has reported its financial results for the second quarter of 2026, highlighting significant advancements in its clinical programs. The company has initiated the Phase 3 ACCOMPLISH program for aleniglipron, an oral GLP-1 receptor agonist aimed at chronic weight management. Additionally, data from the Phase 1 SAD trial of ACCG-2671, a dual amylin and calcitonin receptor agonist, was shared, along with the initiation of the MAD clinical trial.
Read more →GPCRStructure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
Structure Therapeutics has announced a publication in Nature Medicine showcasing results from its Phase 2b ACCESS program for aleniglipron, a GLP-1 receptor agonist designed for obesity treatment. The study demonstrated dose-dependent and statistically significant weight loss reductions, with continued effectiveness noted beyond 36 weeks of treatment. The Phase 3 program is on track to begin in Q3 2026, aiming to expand the treatment options for patients with obesity. The safety profile aligns with known GI-related adverse effects typical of the GLP-1 class but showed favorable tolerability.
Read more →GPCRStructure Therapeutics Announces Participation in Upcoming Investor Conferences
Structure Therapeutics Inc. announced its participation in two healthcare conferences in June 2026. The company, which focuses on developing oral small molecule therapeutics for metabolic diseases, particularly obesity, will provide live and archived webcasts accessible through its website. This initiative highlights its commitment to engaging with investors and promoting its innovative pipeline.
Read more →GPCRStructure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Structure Therapeutics has reported positive financial results for the first quarter of 2026, highlighting successful outcomes from the aleniglipron Phase 2 ACCESS II study. The company is positioned to initiate Phase 3 clinical trials for aleniglipron, focusing on chronic weight management. Additionally, Structure Therapeutics maintains a robust cash reserve of $1.5 billion, which supports its operations through the end of 2028. Upcoming presentations at the American Diabetes Association meeting will further showcase aleniglipron and the company’s other metabolic disease candidates.
Read more →GPCRStructure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
Structure Therapeutics will present multiple studies at the ADA 86th Scientific Sessions, focusing on aleniglipron, an oral GLP-1 receptor agonist. Key presentations include findings from the ACCESS Phase 2b trial, which highlights significant weight loss in obese patients. Additional studies will explore safety, tolerability, and combination treatments with amylin receptor agonists.
Read more →GPCRStructure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
Structure Therapeutics has appointed Matthew Lang, J.D., as Chief Operating Officer and General Counsel. Lang brings over fifteen years of experience in biopharmaceutical leadership, having previously held significant roles at Metsera and Myovant Sciences. His expertise will be crucial as the company progresses aleniglipron into Phase 3 trials, aiming to address obesity with innovative therapies.
Read more →GPCR▲ +5.4%on this news
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with
Structure Therapeutics announced positive topline results from the Phase 2 ACCESS II trial of aleniglipron, a small molecule GLP-1 receptor agonist. At 44 weeks, patients experienced a mean weight loss of 16.3% with the 180 mg dose. The drug exhibited a good safety profile, with low rates of adverse event-related discontinuations. The company is moving forward with plans for a Phase 3 trial, anticipated to begin in the second half of 2026, following an end-of-Phase 2 meeting with the FDA scheduled for the second quarter of 2026.
Read more →GPCRStructure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Structure Therapeutics reported positive financial results for Q4 and full year 2025, highlighted by significant weight loss data from the aleniglipron Phase 2 ACCESS programs. The company maintains a strong cash position of $1.4 billion, allowing it to fund operations well into 2028. Anticipation builds for the initiation of Phase 3 trials for aleniglipron and upcoming data releases. Despite recent successes, the company also faces challenges, including increased R&D expenses and a substantial net loss for the year.
Read more →GPCRStructure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Structure Therapeutics has launched a Phase 1 clinical study for ACCG-2671, an oral amylin receptor agonist aimed at treating obesity. This study will assess the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers and individuals with obesity. The company believes that amylin-based therapies could significantly enhance obesity treatment options.
Read more →GPCRStructure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
Structure Therapeutics Inc. has announced the successful closing of its upsized public offering, raising approximately $747.5 million. The offering involved nearly 10 million American depositary shares (ADSs) and included the full exercise of underwriters' options for additional purchases. Financial institutions like Jefferies, Goldman Sachs, and Morgan Stanley played significant roles as managers of the offering. Funds raised will support the company's focus on developing innovative therapies for obesity and other metabolic conditions.
Read more →GPCRStructure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
Structure Therapeutics Inc. has announced the pricing of its upsized public offering of American depositary shares totaling approximately $650 million. The offering consists of 8,461,538 ADSs priced at $65.00 each and warrants at $64.9999. The offering aims to raise funds for the company’s ongoing development of oral small molecule therapeutics targeting metabolic diseases. This transaction is expected to close on December 11, 2025, pending customary closing conditions.
Read more →GPCR▲ +102.5%on this newsshared move
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Structure Therapeutics reported encouraging topline data from its ACCESS program for aleniglipron, an oral GLP-1 receptor agonist aimed at treating obesity. In a 36-week Phase 2b study, a placebo-adjusted mean weight loss of 11.3% was achieved at the 120 mg dose, while up to 15.3% weight loss was observed with the 240 mg dose in exploratory studies. The company plans to advance aleniglipron into Phase 3 clinical development by mid-2026, emphasizing a strong tolerability profile and a positive safety record for an oral therapy. This development could enhance treatment options for obesity, a complex disease affecting many individuals.
Read more →GPCR▲ +102.5%on this newsshared move
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
Structure Therapeutics Inc. plans to release topline data from its ACCESS clinical program for aleniglipron, an oral GLP-1 receptor agonist targeting obesity, on December 8, 2025. This announcement highlights the company's commitment to developing novel therapies for metabolic diseases. A conference call will follow the data release for further discussion.
Read more →GPCR▲ +102.5%on this newsshared move
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants
Structure Therapeutics Inc. has announced a proposed underwritten public offering of $500 million of American depositary shares (ADSs) to support its clinical-stage portfolio. The offering includes a 30-day option for underwriters to purchase an additional $75 million in ADSs. The company is focused on developing innovative therapies for metabolic conditions, supported by its GPCR-targeted pipeline. However, the actual completion and terms of the offering remain uncertain due to market conditions and other factors.
Read more →About Structure Therapeutics Inc.
Headquarters601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next GPCR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime